TP53 and neoplasm: Overall, these results demonstrated the administration of ReACp53 resulted in a reduced tumor burden in mice bearing OVCAR3 human ovarian cancer cells, but not p53-null SKOV3 cells using a physiologic intraperitoneal disease model.